Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans

• Main Authors: Donghong Xu (Author), Punag Divanji (Author), Adrienne Griffith (Author), Rajaa Sukhun (Author), Kathleen Cheplo (Author), Jianlin Li (Author), Polina German (Author)
• Format: Book
• Published: Wiley, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten. Eight healthy male participants received a single or...